Viewing nowCombinationJanux XR Extended-Release Tablet 100/1000 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.

MFDS item code 202201875 · Approved 2022.05.09 · Insurance code 649703040,653806540
Improves blood glucose control in patients with type 2 diabetes
This medication is used to help control blood glucose levels in patients with type 2 diabetes. It contains both sitagliptin and metformin, which can effectively manage blood glucose levels when combined with dietary and exercise therapy. Consistent use and improvement of lifestyle habits can aid in alleviating diabetes symptoms.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug treatment and inadequate glycemic control with monotherapy, or patients inadequately controlled with sitagliptin monotherapy, the initial dose of this medicine is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If this initial dose does not provide adequate glycemic control, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients inadequately controlled with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients inadequately controlled with combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is a total daily dose of sitagliptin 100 mg, and the initial metformin dose should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; caution should therefore be exercised and appropriate monitoring performed. Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1,000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication contains two components, sitagliptin and metformin, and is primarily used to assist in blood glucose control in patients with type 2 diabetes. First, the sitagliptin component may cause serious allergic reactions in some patients, so if symptoms such as rash, hives, or difficulty breathing occur, the medication should be stopped immediately and a doctor consulted. Additionally, sitagliptin may cause inflammation of the pancreas (pancreatitis), so any symptoms such as abdominal pain, vomiting, or nausea should be reported to a healthcare professional immediately. The metformin component can cause a rare but serious condition known as lactic acidosis, which can be life-threatening, so if symptoms such as muscle pain, difficulty breathing, fatigue, or abdominal pain occur, immediate medical treatment is required. This medication should not be prescribed to patients with moderately or severely impaired kidney function, acute infection, dehydration, severe heart failure, or acute myocardial infarction. It is also not recommended for pregnant women, women who may become pregnant, nursing mothers, or children under 18. While taking this medication, it is important to maintain regular meals and exercise, as irregular meals or excessive exercise can lead to hypoglycemia or other side effects. When used in conjunction with other blood glucose lowering drugs or insulin, the risk of hypoglycemia may increase, so awareness of hypoglycemia symptoms is important and dosage adjustments with a physician may be necessary. While taking this medication, regular kidney function and blood tests should be conducted, particularly as vitamin B12 levels may decrease, so periodic testing is recommended. If surgical or radiological imaging tests are planned, the medication should be temporarily discontinued, and resuming use should be determined after kidney function has recovered. Additionally, alcohol consumption should be avoided during treatment, as excessive drinking can increase the risk of side effects. Finally, patients taking this medication should be well-informed about the symptoms of hypoglycemia and lactic acidosis, and report any unusual symptoms to healthcare providers immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture, and should be kept at a temperature between 1 to 30 degrees Celsius. Storing it in this manner will help maintain its effectiveness for a longer period.
Bright blue, oval shaped, biconvex, extended-release film-coated tablet
28 tablets/bottle, 30 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hunguk Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.